什么年龄是太老了? 在老年患者中关闭卵孔
Carlos Vazquez-Sosa1, Stacey D Clegg1,2, James C Blankenship1
1University of New Mexico Health Science Center Albuquerque, NM.
US cardiology
|December 25, 2024
概括
专利卵孔 (PFO) 关闭有效地预防了年轻人反复发生的密码性中风. 然而,由于同时存在的风险因素和有限的试验数据,其对老年人的益处仍然不确定.
科学领域:
- 心脏病学 心脏病学
- 神经学 神经学
- 血管医学 血管医学
背景情况:
- 专利卵孔 (PFO) 关闭已被证明可以降低复发的密码性中风风险,主要是在年轻的患者中.
- 关键的随机对照试验排除了60岁以上的个人,限制了老年人群中PFO关闭的证据.
- 老年人经常出现并发症,这些并发症是独立的中风风险因素,这复杂化了对PFO作用的评估.
研究的目的:
- 审查PFO关闭的历史和当前证据,特别关注老年人.
- 讨论评估和治疗PFO老年患者密码性中风的挑战.
- 为突出这一人口群体需要进一步的研究和指导方针.
主要方法:
- 文献综述侧重于PFO关闭和密码性中风的研究.
- 对现有随机对照试验数据的分析,并注明排除标准.
- 讨论PFO和中风的老年患者的临床考虑.
主要成果:
- PFO关闭试验主要包括年轻患者,显示出显著的益处.
- 在60岁以上的患者中,PFO关闭的有效性和安全性的数据很少.
- 加密性中风和PFO的老年患者越来越多地被转诊到心脏病学,但缺乏具体的管理指南.
结论:
- 在老年人中,PFO关闭对于复发性密码性中风的好处尚未得到充分证实.
- 进一步的临床试验对于指导老年人群中PFO的评估和治疗至关重要.
- 目前的做法需要仔细考虑个别的风险因素和老年患者的有限证据.
相关概念视频
Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Mitral Stenosis IV: Nursing Management
A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...


